Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)

被引：4

作者：

Hajek, Roman ^{[1
]}

Terpos, Evangelos ^{[2
]}

Lee, Hans C. ^{[3
]}

Chari, Ajai ^{[4
]}

Costello, Caitlin L. ^{[5
]}

Puig, Noemi ^{[6
]}

Leleu, Xavier ^{[7
]}

Berdeja, Jesus G. ^{[8
]}

Davies, Faith E. ^{[9
]}

Weisel, Katja ^{[10
]}

Usmani, Saad Z. ^{[11
]}

Hungria, Vania T. M. ^{[12
,13
]}

Boccadoro, Mario ^{[14
]}

Rifkin, Robert M. ^{[15
]}

Zonder, Jeffrey A. ^{[16
]}

Cook, Gordon ^{[17
]}

Brozova, Lucie ^{[18
]}

Barinova, Magda ^{[19
]}

Ren, Kaili ^{[20
]}

Cacioppo, Roxanne ^{[21
]}

Skacel, Tomas ^{[21
]}

Stull, Dawn Marie ^{[22
]}

Maisnar, Vladimir ^{[23
,24
]}

机构：

[1] Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[2] Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[4] Mt Sinai Sch Med, New York, NY USA

[5] Univ Calif San Diego, Dept Med, Div Blood & Marrow Transplantat, Moores Canc Ctr, La Jolla, CA 92093 USA

[6] Hosp Univ Salamanca, Hematol Dept, Salamanca, Spain

[7] CHU Poitiers, Pole Reg Cancerol, Poitiers, France

[8] Sarah Cannon Res Inst, Dept Hematol, Nashville, TN USA

[9] UAMS, Winthrop P Rockefeller Canc Inst, Myeloma Inst Res & Therapy, Little Rock, AR USA

[10] Univ Klinikum Tubingen, Tubingen, Germany

[11] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[12] Clin Sao Germano, Dept Hematol, Sao Paulo, Brazil

[13] Santa Casa Med Sch, Sao Paulo, Brazil

[14] Univ Torino, Div Hematol, Myeloma Unit, Turin, Italy

[15] US Oncol Res, Hematol Res, Rocky Mt Canc Ctr, Yampa Valley Med Ctr, Houston, TX USA

[16] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Malignant Hematol, Detroit, MI USA

[17] Leeds Teaching Hosp, Clin Trials Res Unit, Haematol, NIHR Leeds IVD Cooperat, Leeds, W Yorkshire, England

[18] Inst Biostat & Anal Ltd, Dept Data Anal, Brno, Czech Republic

[19] Inst Biostat & Anal Ltd, Dept Clin Projects, Brno, Czech Republic

[20] Millennium Pharmaceut Inc, Global Stat & Quantitat Sci, Cambridge, MA USA

[21] Millennium Pharmaceut Inc, Cambridge, MA USA

[22] Millennium Pharmaceut Inc, Global Med Affairs, Cambridge, MA USA

[23] Charles Univ Hosp, Dept Med Haematol 4, Hradec Kralove, Czech Republic

[24] Fac Med, Hradec Kralove, Czech Republic

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-113441

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1971

引用

页数：6

共 35 条

[1] Ixazomib plus Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Pooled Analysis from the INSIGHT MM Observational Study and the Czech Registry of Monoclonal Gammopathies
Cook, G.
Hajek, R.
Terpos, E.
Lee, H. C.
Chari, A.
Costello, C. L.
Puig, N.
Leleu, X.
Berdeja, J. G.
Davies, F. E.
Weisel, K. C.
Usmani, S. Z.
Hungria, V. T. M.
Boccadoro, M.
Rifkin, R. M.
Zonder, J. A.
Brozova, L.
Barinova, M.
Ren, K.
Cacioppo, R.
Skacel, T.
Stull, D. M.
Maisnar, V.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 16 - 17
[2] Ixazomib plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (RRMM) patients in real-world experience: a pooled analysis from the INSIGHT MM observational study and the Czech Registry of Monoclonal Gammopathies (RMG)
Weisel, K.
Hajek, R.
Terpos, E.
Lee, H. C.
Chari, A.
Costello, C. L.
Puig, N.
Leleu, X.
Berdeja, J. G.
Davies, F. E.
Usmani, S. Z.
Hungria, V. T. M.
Boccadoro, M.
Rifkin, R. M.
Zonder, J. A.
Cook, G.
Brozova, L.
Barinova, M.
Ren, K.
Skacel, T.
Stull, D. M.
Maisnar, V.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 125 - 125
[3] IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): CHINA CONTINUATION OF TOURMALINE-MM1
Hou, J.
Jin, J.
Xu, Y.
Wu, D.
Ke, X.
Daobin, Z.
Lu, J.
Du, X.
Chen, X.
Li, J.
Liu, J.
Wang, B.
Zhang, X.
Wang, H.
van de Velde, H.
Richardson, P.
Moreau, P.
[J]. HAEMATOLOGICA, 2016, 101 : 540 - 540
[4] Closing the efficacy and effectiveness gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) patients (Pts) treated with Ixazomib-lenalidomide-Dexamethasone (IRd) in routine clinical practice remain comparable to the outcomes reported in the phase 3 TOURMALINE-MM1 study
Weisel, K.
Hajek, R.
Minarik, J.
Straub, J.
Pour, L.
Jungova, A.
Berdeja, J.
Boccadoro, M.
Brozova, L.
Spencer, A.
Van Rhee, F.
Vela-Ojeda, J.
Thompson, M.
Abonour, R.
Chari, A.
Cook, G.
Costello, C.
Davies, F.
Hungria, V
Lee, H. C.
Leleu, X.
Puig, N.
Rifkin, R.
Terpos, E.
Usmani, S.
Zonder, J.
Barinova, M.
Kuhn, M.
Silar, J.
Capkova, L.
Galvez, K.
Lu, J.
Skacel, T.
Elliott, J.
Demers, B.
Stull, D. M.
Ren, K.
Maisnar, V
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 96 - 97
[5] Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study
Hajek, Roman
Minarik, Jiri
Straub, Jan
Pour, Ludek
Jungova, Alexandra
Berdeja, Jesus G.
Boccadoro, Mario
Brozova, Lucie
Spencer, Andrew
van Rhee, Frits
Vela-Ojeda, Jorge
Thompson, Michael A.
Abonour, Rafat
Chari, Ajai
Cook, Gordon
Costello, Caitlin L.
Davies, Faith E.
Hungria, Vania T. M.
Lee, Hans C.
Leleu, Xavier
Puig, Noemi
Rifkin, Robert M.
Terpos, Evangelos
Usmani, Saad Z.
Weisel, Katja C.
Zonder, Jeffrey A.
Barinova, Magda
Kuhn, Matyas
Silar, Jiri
Capkova, Lenka
Galvez, Kenny
Lu, Jin
Skacel, Tomas
Elliott, Jennifer
Demers, Brittany
Marie, Dawn
Ren, Kaili
Maisnar, Vladimir
[J]. BLOOD, 2019, 134
[6] Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Richardson, Paul G.
Kumar, Shaji K.
Masszi, Tamas
Grzasko, Norbert
Bahlis, Nizar J.
Hansson, Markus
Pour, Ludek
Sandhu, Irwindeep
Ganly, Peter
Baker, Bartrum W.
Jackson, Sharon R.
Stoppa, Anne-Marie
Gimsing, Peter
Garderet, Laurent
Touzeau, Cyrille
Buadi, Francis K.
Laubach, Jacob P.
Cavo, Michele
Darif, Mohamed
Labotka, Richard
Berg, Deborah
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) : 2430 - +
[7] Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1.
Hou, Jian
Jin, Jie
Xu, Yan
Wu, Depei
Ke, Xiaoyan
Zhou Daobin
Lou, Jin
Du, Xin
Chen, Xiequn
Li, Junmin
Liu, Jing
Wang, Bingxia
Zhang, Xiaoquan
Wang, Hui
Van De Velde, Helgi
Richardson, Paul G.
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma
Hari, Parameswaran
Lin, Huamao Mark
Zhu, Yanyan
Berg, Deborah
Richardson, Paul G.
Moreau, Philippe
[J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 793 - 798
[9] Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1
Hou, Jian
Jin, Jie
Xu, Yan
Wu, Depei
Ke, Xiaoyan
Daobin, Zhou
Lu, Jin
Du, Xin
Chen, Xiequn
Li, Junmin
Liu, Jing
Gupta, Neeraj
Hanley, Michael
Li, Hongmei
Hua, Zhaowei
Wang, Bingxia
Zhang, Xiaoquan
Wang, Hui
van de Velde, Helgi
Richardson, Paul
Moreau, Philippe
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E67 - E67
[10] The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
Leleu, Xavier
Boccadoro, Mario
Lee, Hans C.
Zonder, Jeffrey A.
Macro, Magaret
Ramasamy, Karthik
Hulin, Cyrille
Silar, Jiri
Kuhn, Matyas
Ren, Kaili
Bent-Ennakhil, Nawal
Bouillie, Sylvie
Cherepanov, Dasha
Stull, Dawn Marie
Terpos, Evangelos
[J]. BLOOD, 2021, 138

← 1 2 3 4 →